Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Onyx Scientific Invests in New Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Onyx Scientific Invests in New Facility

Prepares for the approval of a commercial API license.

By: Contract Pharma

Contract Pharma Staff

Onyx Scientific is investing in a new facility at its UK site in order to prepare for the approval of a commercial API license.
 
The new facility, which represents a £3 million ($4 million) investment, is currently in the design phase and the building work will begin at the start of 2021, in preparation for the license approval. It will enable the CDMO to meet demand for flexible, small-scale drug substance manufacture, supporting customers from the moment a lead molecule is identified, into Phase I studies and through to commercial manufacture. 
 
The facility is expected to be approximately 30,000 square feet and will be used for non-GMP & GMP Phase I – III and commercial API manufacturing. 
 
New Service
 
Following the license approval, the UK facility will have the capacity to manufacture low volumes of drug substance for the commercial market. This new service will complement Onyx’s facility in North Carolina, U.S, which offers larger scale manufacturing capability.
 
Denise Bowser, commercial director at Onyx Scientific, commented, “The growth of our UK facility is an important milestone for Onyx and means we can help fill the gap in the market for small-scale commercial API requirements. Here at Onyx, we truly care about our customers and their chemistry, treating every molecule as if it were our own. We are excited that following license approval, our team in the UK will be able to guide our customers through the complete journey to market.”
 
In addition to the facility investment, Onyx is currently working on a process validation campaign that will be used to support the commercial API license. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics